Management Team
John L. Warden, Jr.
Founder & CEO
Entrepreneurial and executive roles in 5 start-up companies to date, returning more than $75M in net profits to investors.
Successful business development experience with Biovista, a drug development services provider to major pharmaceutical companies. Significant impact building markets for technology products.
Developed, engineered and constructed the proprietary software and hardware for the HemChip®, HemBox™, and HemStation™.
Sang Xuan Hai Dinh
Chief Development Officer
Sang Dinh is multi-sector entrepreneur and founder with a distinguished track record in developing sustainable business models across renewable energy (hydropower and solar), education, and healthcare. Boasting over 25 years of leadership experience, he possess expertise in executive management, strategic planning, finance, and investment.
Mr. Dinh have successfully participated in and executed numerous M&A deals and corporate restructurings. His profile features sharp strategic thinking and practical execution combined with strong operational capabilities, focusing on optimizing operational efficiency, scaling business growth, and driving long-term value creation.
David Ho, PhD
Founder, President & CSO
An acknowledged expert on blood platelets who has been at the forefront of blood research for over a decade. Dr. Ho is well-published and has expanded the understanding of how coagulation protein factor XI interacts with platelets.
Inventor of an unique desiccation technique to preserve human cells for extended storage. He has been issued three US patents and numerous scientific awards.
Has directed numerous inter-organizational projects with academic, government and industry partners for cellular products in wound dressing, tissue regeneration and transfusable applications.
Richard Liu
CFO
Extensive professional experiences in capital markets, financial analysis, accounting and auditing ​MBA from Johnson Graduate School of Management, Cornell University; BBA from Baruch College, City University of New York.
He is a CFA Charterholder and was a CPA in New York State.​ Successfully oversaw equity trading desk with hundreds of millions of shares of trading volume in the US, EU, and Japan and brought direct positive impact to P&L by leveraging technology to improve execution speed and quality with lower commissions.
Srivatsa Aithal, PhD
Director of R&D
Sri Aithal pursued his Post-Doc at McMaster University and Ph.D. at Sherbrooke University in Canada.
He drove the effort to commercialize impedance spectroscopy-based sensing at Abnova, Taiwan.
He was also a Co-Founder of Celerite Labs, a startup company commercializing magnetic bio-printing technology that accelerated drug discovery.
Sri has several journal publications and an approved patent.
